HK inno.N also closed higher amid expectations for U.S. FDA approval of its gastroesophageal reflux disease treatment, K-CAB, in January 2027. Meanwhile, Bioneer attracted investor interest with its proprietary RNA interference (RNAi) platform and potential global licensing opportunities.
(Graphic by ChatGPT)
The pharmaceutical sector declined 1.34%, while the biotechnology sector fell 2.50%. Among 161 pharmaceutical stocks, only 18 advanced, while 131 ended lower. In the biotechnology sector, 68 of 93 stocks closed below their previous trading day's levels.
◇Hanmi’s Obesity Drug Epe Sells Out Initial Supply
Hanmi Pharmaceutical surged after reports that the initial supply of its domestically developed obesity treatment, Epe, worth approximately KRW 10 billion, had been exhausted ahead of expectations. The rapid depletion of initial inventory following the start of domestic prescriptions fueled optimism about future sales growth.
According to KG Zeroin's MP Doctor, Hanmi Pharmaceutical closed at KRW 449,000, up KRW 27,000, or 6.40%, from the previous session. Its strong performance contrasted with a broader market selloff that saw both the KOSPI and KOSDAQ indices plunge more than 5% during intraday trading.
The primary driver behind the rally was growing confidence in Epe's commercial potential. The drug, which became available for domestic prescriptions on October 29, exhausted its initial supply worth approximately KRW 10 billion within two business weeks.
Analysts attributed the strong early demand partly to Hanmi's competitive pricing strategy. The introductory four-week supply price was set at KRW 129,800, roughly half that of competing obesity treatment Mounjaro.
Recent clinical data further strengthened investor confidence. On November 16, Hanmi presented 64-week results from Epe's Phase 3 clinical trial involving 448 Korean adults with obesity or overweight at a U.S. obesity conference.
The average weight reduction reached 10.56%, an improvement of 0.81 percentage points from the previously reported 9.75% reduction at 40 weeks.
Expectations surrounding Hanmi's next-generation obesity drug pipeline also supported the stock.
Hanmi Pharmaceutical’s Epe, South Korea’s first domestically developed GLP-1 obesity drug. (Photo courtesy of Hanmi Pharmaceutical)
Shin Ji-hoon, an analyst at KB Securities, projected that Hanmi's triple-agonist obesity drug candidate, zantrutide (HM15275), could attract licensing opportunities following the anticipated completion of its U.S. Phase 2 trial in the first half of 2027.
Another obesity treatment candidate, HM17321, already licensed to Roche, is also expected to complete Phase 1 clinical trials during the same period.
Hanmi plans to build on Epe's early market momentum by gradually expanding production and broadening its distribution network to hospitals, clinics and pharmacies nationwide starting in January 2027.
A Hanmi Pharmaceutical official said, "Our medium- to long-term goal is to increase Epe sales to KRW 200 billion."
HK inno.N Gains 2.26% on Expectations for U.S. Approval of K-CAB and 23% Earnings Growth
HK inno.N closed higher on growing expectations for the U.S. market entry of K-CAB, its treatment for gastroesophageal reflux disease. The anticipated FDA decision in January 2027, combined with a recovery in domestic sales, has strengthened expectations for improved earnings.
◇HK inno.N Eyes U.S. Market Entry With K-CAB in 2027
The potential U.S. launch of K-CAB was a key factor behind investor optimism.
KB Securities maintained its Buy rating and KRW 70,000 price target for HK inno.N. The brokerage forecast 2027 revenue of KRW 1.1204 trillion, representing a 4.4% year-on-year increase, and operating profit of KRW 159.2 billion, up 22.8%.
K-CAB's U.S. entry is considered a major potential catalyst for the company's valuation.
If the drug receives FDA approval in January 2027, HK inno.N is expected to begin receiving milestone payments and royalties tied to U.S. sales. KB Securities projected that annual U.S. sales of K-CAB could reach approximately USD 400 million by 2031.
The U.S. market environment is also becoming more favorable.
Voquezna, a competing treatment in the same potassium-competitive acid blocker (P-CAB) class, generated USD 84.7 million in third-quarter revenue, an increase of 71% from a year earlier.
Analysts believe the commercial progress of existing P-CAB treatments could reduce market entry barriers for K-CAB by increasing physician awareness and establishing prescribing practices.
K-CAB. (Photo=HK inno.N)
Domestic business performance is also expected to improve.
K-CAB's third-quarter outpatient prescription value reached KRW 65.4 billion, up 16.5% year-on-year. However, reported domestic revenue declined 15% due to drug-price rebate accounting adjustments and inventory management.
Analysts expect these temporary factors to ease, allowing prescription growth to translate more directly into revenue expansion in 2027.
Shin Ji-hoon of KB Securities said, "The fact that existing treatments have already experienced the challenges of entering the U.S. market, while improving insurance coverage procedures and physician awareness, is positive."
He added, "K-CAB will enter a market where much of the groundwork has already been laid, giving it an advantage during the initial launch period."
Bioneer Highlights RNAi Drug Platform in Europe, Explores Global Licensing Opportunities
Bioneer sought to expand international collaboration opportunities by presenting its proprietary RNA interference technology at one of Europe's largest pharmaceutical and biotechnology partnering events.
The company announced on November 20 that it had conducted approximately 20 one-on-one meetings with global pharmaceutical companies and major European medical institutions during BIO-Europe 2026, recently held in Cologne, Germany.
◇Bioneer Eyes Global Deals for RNAi Platform
At the event, Bioneer highlighted its proprietary SAMiRNA platform, which uses nanoparticles to deliver small interfering RNA (siRNA) to targeted tissues.
The technology is designed for localized administration, reducing systemic exposure while delivering therapeutic effects to specific tissues.
Bioneer has already commercialized CosmeRNA, a hair-care cosmetic product based on the platform. The company is now developing a next-generation hair-loss treatment designed to act directly on hair follicles.
CosmeRNA. (Photo=Bioneer)
Its objective is to address potential hormone-related systemic side effects associated with conventional oral hair-loss medications.
Another major focus of the partnering discussions was SRN001, an investigational treatment for fibrotic diseases.
SRN001 is designed to selectively inhibit amphiregulin (AREG), a protein associated with fibrosis. The candidate is currently undergoing the multiple ascending dose portion of a Phase 1b clinical trial.
Bioneer plans to advance discussions with global pharmaceutical companies regarding potential licensing agreements once additional clinical data become available.
The company also held meetings with three major European hospitals to explore opportunities in molecular diagnostics.
Bioneer introduced its point-of-care molecular diagnostic system, IRON-qPCR, and its automated high-throughput molecular diagnostic platform, ExiStation FA 96. Discussions included potential clinical evaluations of the equipment at European medical institutions.
A Bioneer official said, "Global RNAi drug development is shifting its focus beyond liver diseases toward extrahepatic tissues, including fat, muscle, lungs and skin."
The official added, "We will continue follow-up discussions with the partners we met at the event and demonstrate tangible progress through SRN001 clinical data and molecular diagnostic evaluations."









